This study is being done to find out whether adding a drug called liposomal irinotecan to standard combination therapy will be more active against advanced EGA than standard treatment. Liposomal irinotecan is a new chemotherapy drug that has been approved by the FDA to treat pancreatic cancer. Researchers think that combining liposomal irinotecan with a standard combination chemotherapy regimen will be beneficial against EGA as well. Combining three chemotherapy drugs has been shown to be more potent against this cancer in the past. However, older drugs have had more side effects. Researchers hope that the new combination will be active and less toxic. However, this treatment may have bad side effects, even if it shrinks tumors.
P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Cancers
OPEN TO ACCRUAL